 |
Case Report
0.19 mg Fluocinolone acetonide implant (ILUVIEN) in the treatment of birdshot chorioretinopathy: A case report
1 Department of Ophthalmology, University Hospital Galway, Galway City, Co. Galway, Ireland
Address correspondence to:
Shane Whitlow
Department of Ophthalmology, University Hospital Galway, Galway City, Co. Galway,
Ireland
Message to Corresponding Author
Article ID: 100025Z17SW2022
Access full text article on other devices
Access PDF of article on other devices
How to cite this article
Whitlow S, O’Dwyer G, Townley D. 0.19 mg Fluocinolone acetonide implant (ILUVIEN) in the treatment of birdshot chorioretinopathy: A case report. J Case Rep Images Opthalmol 2022;5:100025Z17SW2022.ABSTRACT
Introduction: Birdshot choroidopathy (BCR) is a non-infectious posterior uveitis. Long-lasting resolution of BCR associated cystoid macular edema (CME) can be difficult to achieve with current accepted treatments due to its high rate of recurrence. A 0.19 mg fluocinolone acetonide implant (FA; ILUVIEN, Alimera Sciences Ltd., Hampshire, UK) is a slow release, intravitreal, non-biodegradable corticosteroid implant that can be used in the management of recurrent non-infectious uveitis affecting the posterior segment of the eye. We report a case following treatment of recurrent BCR associated CME with the FA implant.
Case Report: This case is from a patient diagnosed with BCR with recurrent CME, which failed to resolve following multiple dexamethasone implant administrations. Following delivery of the FA implant, a sustained improvement in best-corrected visual acuity and central macular thickness was observed.
Conclusion: Based on current data, we recommend consideration of treatment with the FA implant
Keywords: Birdshot choroidopathy, Cystoid macular edema, Fluocinolone acetonide, ILUVIEN, Ozurdex, Uveitis
SUPPORTING INFORMATION
Author Contributions
Shane Whitlow - Substantial contributions to conception and design, Acquisition of data, Analysis of data, Interpretation of data, Drafting the article, Revising it critically for important intellectual content, Final approval of the version to be published
Gareth O’Dwyer - Substantial contributions to conception and design, Acquisition of data, Analysis of data, Interpretation of data, Drafting the article, Revising it critically for important intellectual content, Final approval of the version to be published
Deirdre Townley - Substantial contributions to conception and design, Interpretation of data, Drafting the article, Final approval of the version to be published
Guaranter of SubmissionThe corresponding author is the guarantor of submission.
Source of SupportNone
Consent StatementWritten informed consent was obtained from the patient for publication of this article.
Data AvailabilityAll relevant data are within the paper and its Supporting Information files.
Conflict of InterestAuthors declare no conflict of interest.
Copyright© 2022 Shane Whitlow et al. This article is distributed under the terms of Creative Commons Attribution License which permits unrestricted use, distribution and reproduction in any medium provided the original author(s) and original publisher are properly credited. Please see the copyright policy on the journal website for more information.
